Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BISICHEM CO., LTD. operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio has 1 pending office action, reflecting a targeted stage of its intellectual property development. This action is being handled by 1 distinct examiner, concentrating the company's current USPTO engagement on a single point of review. The portfolio's activity is also limited to 1 distinct art unit, indicating that the pending matter falls within a specific technical niche of the biotechnology field.
The busiest examiner for BISICHEM CO., LTD. is HERNANDEZ, JACKSON J, who is currently overseeing the 1 pending office action. As the only examiner with an active case, HERNANDEZ, JACKSON J holds a critical role in determining the outcome of the company's current patenting efforts. For a practitioner, the fact that there is 1 busiest examiner pending case simplifies the management of the portfolio but increases the importance of this specific interaction. The concentration in 1 distinct art unit suggests that the company is not currently facing the challenge of navigating multiple different examination standards across the USPTO.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17947527 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | HERNANDEZ, JACKSON J | 71d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17947527 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | HERNANDEZ, JACKSON J | 71d overdue |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17947527 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | HERNANDEZ, JACKSON J | 1627 | §101§112 | Non-Final OA | 71d overdue | Pending | Sep 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBISICHEM CO., LTD. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jackson J Hernandez has the most, with 1 of BISICHEM CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
